Adverse impact of 1q amplification on outcomes in patients with multiple myeloma treated with daratumumab, carfilzomib and dexamethasone in a real‐world clinical setting
Gespeichert in:
| Veröffentlicht in: | Hematological oncology 2024-09, Vol.42 (5), p.e3306-n/a |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 5 |
| container_start_page | e3306 |
| container_title | Hematological oncology |
| container_volume | 42 |
| creator | Kikuchi, Taku Tsukada, Nobuhiro Kunisada, Kodai Matsumoto, Chiaki Nomura‐Yogo, Moe Oda, Yuki Sato, Kota Takei, Tomomi Ogura, Mizuki Abe, Yu Suzuki, Kenshi Hosoya, Osamu Ishida, Tadao |
| description | |
| doi_str_mv | 10.1002/hon.3306 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3090949744</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3090949744</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2406-9db89c122eaa73cacf748115d93d790cb83e1f1373af57268f2de82f189671fd3</originalsourceid><addsrcrecordid>eNp1kc1qFEEQxxtRzBoFn0AavHhwYn9MZqaPIagRgrnoeajtrnY79MekuyfrevIRfA_fyidx1o0KglBQUPWrHwV_Qp5ydsIZE682KZ5Iybp7ZMWZUg1nnbpPVkz0Q8OEFEfkUSnXjC07NjwkR1JxwVjLVuT7mbnFXJC6MIGuNFnKbyiEyTvrNFSXIt3XXHUKWKiLdFqmGGuhW1c3NMy-uskjDTv0KQCtGaGiOWwNZKhzmAOsX1IN2Tr_JQW3phANNfgZAtYNlBRxbwa63PofX79tU_aGau_i8oOnBWt18dNj8sCCL_jkrh-Tj29efzi_aC6v3r47P7tstGhZ1yizHpTmQiBALzVo27cD56dGSdMrpteDRG657CXY0150gxUGB2H5oLqeWyOPyYuDd8rpZsZSx-CKRu8hYprLKJliqlV92y7o83_Q6zTnuHw3Ss4GxVvZtX-FOqdSMtpxyi5A3o2cjfsAxyXAcR_ggj67E87rgOYP-DuxBWgOwNZ53P1XNF5cvf8l_AklHqhp</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3108914364</pqid></control><display><type>article</type><title>Adverse impact of 1q amplification on outcomes in patients with multiple myeloma treated with daratumumab, carfilzomib and dexamethasone in a real‐world clinical setting</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Kikuchi, Taku ; Tsukada, Nobuhiro ; Kunisada, Kodai ; Matsumoto, Chiaki ; Nomura‐Yogo, Moe ; Oda, Yuki ; Sato, Kota ; Takei, Tomomi ; Ogura, Mizuki ; Abe, Yu ; Suzuki, Kenshi ; Hosoya, Osamu ; Ishida, Tadao</creator><creatorcontrib>Kikuchi, Taku ; Tsukada, Nobuhiro ; Kunisada, Kodai ; Matsumoto, Chiaki ; Nomura‐Yogo, Moe ; Oda, Yuki ; Sato, Kota ; Takei, Tomomi ; Ogura, Mizuki ; Abe, Yu ; Suzuki, Kenshi ; Hosoya, Osamu ; Ishida, Tadao</creatorcontrib><identifier>ISSN: 0278-0232</identifier><identifier>ISSN: 1099-1069</identifier><identifier>EISSN: 1099-1069</identifier><identifier>DOI: 10.1002/hon.3306</identifier><identifier>PMID: 39120040</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Aged ; Antibodies, Monoclonal - administration & dosage ; Antibodies, Monoclonal - adverse effects ; Antibodies, Monoclonal - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Dexamethasone ; Dexamethasone - administration & dosage ; Dexamethasone - adverse effects ; Dexamethasone - therapeutic use ; Female ; Gene Amplification ; Humans ; Immunotherapy ; Inhibitor drugs ; Male ; Middle Aged ; Monoclonal antibodies ; Multiple myeloma ; Multiple Myeloma - drug therapy ; Multiple Myeloma - genetics ; Oligopeptides - administration & dosage ; Oligopeptides - adverse effects ; Oligopeptides - therapeutic use ; Targeted cancer therapy ; Treatment Outcome</subject><ispartof>Hematological oncology, 2024-09, Vol.42 (5), p.e3306-n/a</ispartof><rights>2024 John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2406-9db89c122eaa73cacf748115d93d790cb83e1f1373af57268f2de82f189671fd3</cites><orcidid>0000-0002-3210-7756</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fhon.3306$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fhon.3306$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39120040$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kikuchi, Taku</creatorcontrib><creatorcontrib>Tsukada, Nobuhiro</creatorcontrib><creatorcontrib>Kunisada, Kodai</creatorcontrib><creatorcontrib>Matsumoto, Chiaki</creatorcontrib><creatorcontrib>Nomura‐Yogo, Moe</creatorcontrib><creatorcontrib>Oda, Yuki</creatorcontrib><creatorcontrib>Sato, Kota</creatorcontrib><creatorcontrib>Takei, Tomomi</creatorcontrib><creatorcontrib>Ogura, Mizuki</creatorcontrib><creatorcontrib>Abe, Yu</creatorcontrib><creatorcontrib>Suzuki, Kenshi</creatorcontrib><creatorcontrib>Hosoya, Osamu</creatorcontrib><creatorcontrib>Ishida, Tadao</creatorcontrib><title>Adverse impact of 1q amplification on outcomes in patients with multiple myeloma treated with daratumumab, carfilzomib and dexamethasone in a real‐world clinical setting</title><title>Hematological oncology</title><addtitle>Hematol Oncol</addtitle><subject>Aged</subject><subject>Antibodies, Monoclonal - administration & dosage</subject><subject>Antibodies, Monoclonal - adverse effects</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Dexamethasone</subject><subject>Dexamethasone - administration & dosage</subject><subject>Dexamethasone - adverse effects</subject><subject>Dexamethasone - therapeutic use</subject><subject>Female</subject><subject>Gene Amplification</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Inhibitor drugs</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Monoclonal antibodies</subject><subject>Multiple myeloma</subject><subject>Multiple Myeloma - drug therapy</subject><subject>Multiple Myeloma - genetics</subject><subject>Oligopeptides - administration & dosage</subject><subject>Oligopeptides - adverse effects</subject><subject>Oligopeptides - therapeutic use</subject><subject>Targeted cancer therapy</subject><subject>Treatment Outcome</subject><issn>0278-0232</issn><issn>1099-1069</issn><issn>1099-1069</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc1qFEEQxxtRzBoFn0AavHhwYn9MZqaPIagRgrnoeajtrnY79MekuyfrevIRfA_fyidx1o0KglBQUPWrHwV_Qp5ydsIZE682KZ5Iybp7ZMWZUg1nnbpPVkz0Q8OEFEfkUSnXjC07NjwkR1JxwVjLVuT7mbnFXJC6MIGuNFnKbyiEyTvrNFSXIt3XXHUKWKiLdFqmGGuhW1c3NMy-uskjDTv0KQCtGaGiOWwNZKhzmAOsX1IN2Tr_JQW3phANNfgZAtYNlBRxbwa63PofX79tU_aGau_i8oOnBWt18dNj8sCCL_jkrh-Tj29efzi_aC6v3r47P7tstGhZ1yizHpTmQiBALzVo27cD56dGSdMrpteDRG657CXY0150gxUGB2H5oLqeWyOPyYuDd8rpZsZSx-CKRu8hYprLKJliqlV92y7o83_Q6zTnuHw3Ss4GxVvZtX-FOqdSMtpxyi5A3o2cjfsAxyXAcR_ggj67E87rgOYP-DuxBWgOwNZ53P1XNF5cvf8l_AklHqhp</recordid><startdate>202409</startdate><enddate>202409</enddate><creator>Kikuchi, Taku</creator><creator>Tsukada, Nobuhiro</creator><creator>Kunisada, Kodai</creator><creator>Matsumoto, Chiaki</creator><creator>Nomura‐Yogo, Moe</creator><creator>Oda, Yuki</creator><creator>Sato, Kota</creator><creator>Takei, Tomomi</creator><creator>Ogura, Mizuki</creator><creator>Abe, Yu</creator><creator>Suzuki, Kenshi</creator><creator>Hosoya, Osamu</creator><creator>Ishida, Tadao</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7QP</scope><scope>7T7</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-3210-7756</orcidid></search><sort><creationdate>202409</creationdate><title>Adverse impact of 1q amplification on outcomes in patients with multiple myeloma treated with daratumumab, carfilzomib and dexamethasone in a real‐world clinical setting</title><author>Kikuchi, Taku ; Tsukada, Nobuhiro ; Kunisada, Kodai ; Matsumoto, Chiaki ; Nomura‐Yogo, Moe ; Oda, Yuki ; Sato, Kota ; Takei, Tomomi ; Ogura, Mizuki ; Abe, Yu ; Suzuki, Kenshi ; Hosoya, Osamu ; Ishida, Tadao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2406-9db89c122eaa73cacf748115d93d790cb83e1f1373af57268f2de82f189671fd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Aged</topic><topic>Antibodies, Monoclonal - administration & dosage</topic><topic>Antibodies, Monoclonal - adverse effects</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Dexamethasone</topic><topic>Dexamethasone - administration & dosage</topic><topic>Dexamethasone - adverse effects</topic><topic>Dexamethasone - therapeutic use</topic><topic>Female</topic><topic>Gene Amplification</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Inhibitor drugs</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Monoclonal antibodies</topic><topic>Multiple myeloma</topic><topic>Multiple Myeloma - drug therapy</topic><topic>Multiple Myeloma - genetics</topic><topic>Oligopeptides - administration & dosage</topic><topic>Oligopeptides - adverse effects</topic><topic>Oligopeptides - therapeutic use</topic><topic>Targeted cancer therapy</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kikuchi, Taku</creatorcontrib><creatorcontrib>Tsukada, Nobuhiro</creatorcontrib><creatorcontrib>Kunisada, Kodai</creatorcontrib><creatorcontrib>Matsumoto, Chiaki</creatorcontrib><creatorcontrib>Nomura‐Yogo, Moe</creatorcontrib><creatorcontrib>Oda, Yuki</creatorcontrib><creatorcontrib>Sato, Kota</creatorcontrib><creatorcontrib>Takei, Tomomi</creatorcontrib><creatorcontrib>Ogura, Mizuki</creatorcontrib><creatorcontrib>Abe, Yu</creatorcontrib><creatorcontrib>Suzuki, Kenshi</creatorcontrib><creatorcontrib>Hosoya, Osamu</creatorcontrib><creatorcontrib>Ishida, Tadao</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Hematological oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kikuchi, Taku</au><au>Tsukada, Nobuhiro</au><au>Kunisada, Kodai</au><au>Matsumoto, Chiaki</au><au>Nomura‐Yogo, Moe</au><au>Oda, Yuki</au><au>Sato, Kota</au><au>Takei, Tomomi</au><au>Ogura, Mizuki</au><au>Abe, Yu</au><au>Suzuki, Kenshi</au><au>Hosoya, Osamu</au><au>Ishida, Tadao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adverse impact of 1q amplification on outcomes in patients with multiple myeloma treated with daratumumab, carfilzomib and dexamethasone in a real‐world clinical setting</atitle><jtitle>Hematological oncology</jtitle><addtitle>Hematol Oncol</addtitle><date>2024-09</date><risdate>2024</risdate><volume>42</volume><issue>5</issue><spage>e3306</spage><epage>n/a</epage><pages>e3306-n/a</pages><issn>0278-0232</issn><issn>1099-1069</issn><eissn>1099-1069</eissn><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>39120040</pmid><doi>10.1002/hon.3306</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0002-3210-7756</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0278-0232 |
| ispartof | Hematological oncology, 2024-09, Vol.42 (5), p.e3306-n/a |
| issn | 0278-0232 1099-1069 1099-1069 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3090949744 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Aged Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Dexamethasone Dexamethasone - administration & dosage Dexamethasone - adverse effects Dexamethasone - therapeutic use Female Gene Amplification Humans Immunotherapy Inhibitor drugs Male Middle Aged Monoclonal antibodies Multiple myeloma Multiple Myeloma - drug therapy Multiple Myeloma - genetics Oligopeptides - administration & dosage Oligopeptides - adverse effects Oligopeptides - therapeutic use Targeted cancer therapy Treatment Outcome |
| title | Adverse impact of 1q amplification on outcomes in patients with multiple myeloma treated with daratumumab, carfilzomib and dexamethasone in a real‐world clinical setting |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T16%3A26%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adverse%20impact%20of%201q%20amplification%20on%20outcomes%20in%20patients%20with%20multiple%20myeloma%20treated%20with%20daratumumab,%20carfilzomib%20and%20dexamethasone%20in%20a%20real%E2%80%90world%20clinical%20setting&rft.jtitle=Hematological%20oncology&rft.au=Kikuchi,%20Taku&rft.date=2024-09&rft.volume=42&rft.issue=5&rft.spage=e3306&rft.epage=n/a&rft.pages=e3306-n/a&rft.issn=0278-0232&rft.eissn=1099-1069&rft_id=info:doi/10.1002/hon.3306&rft_dat=%3Cproquest_cross%3E3090949744%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3108914364&rft_id=info:pmid/39120040&rfr_iscdi=true |